Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

NCT01575834 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01575834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01575834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, International, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
March 15, 2012
Completion date
December 28, 2016
Enrollment
7,180 (actual)
Sites
218

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis